At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Stocks in this Quantisnow insightHealth Care
Historical context for ADPT
Across the 14 sessions after earlier ADPT headlines, the stock closed higher 6 times and lower 8 times, with a median move of 4.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ADPT | SPY |
|---|---|---|---|
| May 22, 2026 | Adaptive Biotechnologies to Participate in Upcoming Investor Conferences | +0.1% | +0.4% |
| May 6, 2026 | Adaptive Biotechnologies Reports First Quarter 2026 Financial Results | +4.7% | +1.4% |
| Apr 16, 2026 | Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026 | -3.1% | +0.2% |
| Feb 6, 2026 | Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results | -4.3% | +1.9% |
| Jan 28, 2026 | Adaptive Biotechnologies to Participate in Upcoming Investor Conferences | -3.8% | -0.0% |
| Jan 23, 2026 | Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 | -2.7% | +0.0% |
Quantisnow market dataNASDAQ
ADPT
Adaptive Biotechnologies Corporation
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2019
Get push alerts for ADPT
Full ADPT profile on Quantisnow Follow ADPT and get a push notification the moment its next story breaks.